Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;76(6):988-96.
doi: 10.1111/bcp.12122.

Tacrolimus placental transfer at delivery and neonatal exposure through breast milk

Songmao Zheng  1 , Thomas R Easterling, Karen Hays, Jason G Umans, Menachem Miodovnik, Shannon Clark, Justina C Calamia, Kenneth E Thummel, Danny D Shen, Connie L Davis, Mary F Hebert
Affiliations

Tacrolimus placental transfer at delivery and neonatal exposure through breast milk

Songmao Zheng et al. Br J Clin Pharmacol. 2013 Dec.

Abstract

Aim(s): The current investigation aims to provide new insights into fetal exposure to tacrolimus in utero by evaluating maternal and umbilical cord blood (venous and arterial), plasma and unbound concentrations at delivery. This study also presents a case report of tacrolimus excretion via breast milk.

Methods: Maternal and umbilical cord (venous and arterial) samples were obtained at delivery from eight solid organ allograft recipients to measure tacrolimus and metabolite bound and unbound concentrations in blood and plasma. Tacrolimus pharmacokinetics in breast milk were assessed in one subject.

Results: Mean (±SD) tacrolimus concentrations at the time of delivery in umbilical cord venous blood (6.6 ± 1.8 ng ml(-1)) were 71 ± 18% (range 45-99%) of maternal concentrations (9.0 ± 3.4 ng ml(-1)). The mean umbilical cord venous plasma (0.09 ± 0.04 ng ml(-1)) and unbound drug concentrations (0.003 ± 0.001 ng ml(-1)) were approximately one fifth of the respective maternal concentrations. Arterial umbilical cord blood concentrations of tacrolimus were 100 ± 12% of umbilical venous concentrations. In addition, infant exposure to tacrolimus through the breast milk was less than 0.3% of the mother's weight-adjusted dose.

Conclusions: Differences between maternal and umbilical cord tacrolimus concentrations may be explained in part by placental P-gp function, greater red blood cell partitioning and higher haematocrit levels in venous cord blood. The neonatal drug exposure to tacrolimus via breast milk is very low and likely does not represent a health risk to the breastfeeding infant.

Keywords: breast milk; neonatal exposure; placental transfer; pregnancy; tacrolimus; unbound drug concentration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tacrolimus venous umbilical cord blood : maternal blood, venous umbilical cord plasma : maternal plasma and venous umbilical cord unbound : maternal unbound concentration ratios in eight patients, shown by the time after last dose of tacrolimus to blood sampling. For each ratio, the different data points represent an observation in a different subject. •, venous cord blood : maternal blood (n = 7); ▵, venous cord plasma : maternal plasma (n = 6); formula image, venous cord unbound : maternal unbound (n = 5)
Figure 2
Figure 2
Tacrolimus maternal blood : plasma (n = 7), venous umbilical cord blood : plasma (n = 6) concentration ratios in patients, taking tacrolimus at the time of delivery (A) and the calculated Kbc/p, the tacrolimus partitioning ratio between blood cells and plasma, in maternal blood (n = 7) and venous umbilical cord blood (n = 6) (B). The horizontal lines represent the mean ratios. A) □, maternal blood : maternal plasma; ▴, venous cord blood : venous cord plasma; B) □, maternal blood Kbc/p; ▴, Venous Cord Blood Kbc/p
Figure 3
Figure 3
Tacrolimus concentration (logarithmic scale) in maternal blood, plasma and breast milk (A) and steady-state unbound tacrolimus concentrations in maternal plasma and breast milk (B) of one subject over a single dosing interval. The subject was treated with 1.5 mg of tacrolimus twice daily for immunosuppression. A) formula image, milk; formula image, plasma; formula image, blood; B) formula image, milk unbound drug; formula image, plasma unbound drug
See this image and copyright information in PMC

References

    1. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247–1297. - PubMed
    1. Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V, Warty V, Starzl TE. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997;64:559–565. - PMC - PubMed
    1. Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000;13(Suppl. 1):S299–300. - PubMed
    1. McKay DB, Josephson MA. Pregnancy in recipients of solid organs - effects on mother and child. N Engl J Med. 2006;354:1281–1293. - PubMed
    1. French AE, Soldin SJ, Soldin OP, Koren G. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother. 2003;37:815–818. - PMC - PubMed

Publication types

MeSH terms